Non-infectious Macular Edema Treatment Market is Forecast to Reach US$ 29,567.8 Million by 2034

The global non-infectious macular edema treatment market is projected to reach $15,121.9 million in 2024 and is expected to grow at a CAGR of 6.9%, reaching $29,567.8 million by 2034.

Growth opportunities in emerging economies are anticipated due to pipeline development, where the introduction of new drug candidates holds significant potential for market expansion. A robust pipeline featuring promising compounds signifies the future of therapeutic options, with advancements in clinical trials and successful drug approvals poised to profoundly impact the market.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐚 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.factmr.com/connectus/sample?flag=S&rep_id=9645

Country-wise Insights

By 2034, North America is expected to dominate the global non-infectious macular edema treatment market with a 35.5% share. Pharmaceutical companies in this region are likely to introduce patient assistance programs to enhance treatment accessibility, potentially boosting patient adherence and market growth. In the United States, projected to account for 92.1% of North America's market, the high prevalence of diabetes fuels demand for treatments targeting diabetic macular edema, a common complication of diabetes.

Category-wise Insights

The global demand for non-infectious macular edema treatment is set to rise significantly in the Anti-VEGF segment. Anti-VEGF drugs, administered via intravitreal injections, offer a non-invasive treatment option preferred by patients seeking less invasive procedures. By 2034, the Anti-VEGF segment is forecasted to capture 67.7% of the market share, driven by their effectiveness in reducing macular edema through inhibition of abnormal blood vessel growth in the retina, thereby improving vision and managing associated symptoms.

Read More: Fact.MR Report on Non-Infectious Macular Edema Treatment Market

Competitive Landscape

Key players in the non-infectious macular edema treatment market employ diverse strategies to achieve market leadership. These include fostering innovation, implementing stringent quality control measures, forming strategic partnerships, optimizing supply chain management, and advancing product and technology offerings.

Company Portfolio Highlights:

Allergan Plc: A global pharmaceutical company known for its focus on aesthetics, eye care, central nervous system, and gastroenterology. Allergan has been pivotal in ophthalmology with products like Ozurdex (dexamethasone intravitreal implant), addressing various retinal conditions including macular edema.
Amgen Inc.: A biotechnology leader specializing in innovative biologic medicines, including those for eye care.
Other prominent players in the market include Pfizer Inc., Novartis AG, F. Hoffman - La Roche Ltd., AbbVie Inc., Bayer AG, Valeant Pharmaceuticals Inc., Alimera Sciences Inc., and Clearside Biomedical, Inc. These companies drive competitiveness through comprehensive portfolios and continuous advancements in treatment options for non-infectious macular edema.

Segmentation of Non-infectious Macular Edema Treatment Market Research

By Drug Type :
Anti-VEGF
Corticosteroids
Immunosuppressant
Biologics
Others
By Route of Administration :
Oral
Parental
Topical
By Indication :
Non-Infectious Uveitic ME
Diabetic ME
Retinal Vein Occlusion ME
By Distribution Channel :
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region :
North America
Europe
East Asia
Latin America
Middle East & Africa
South Asia & Oceania

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

𝐀𝐛𝐨𝐮𝐭 𝐅𝐚𝐜𝐭.𝐌𝐑

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.